Dr Franciska Vidáné Erdő

Nationality: 
Hungary
Programme: 
SMART LOIRE VALLEY GENERAL PROGRAMME
Scientific Field: 
Period: 
January, 2022 to April, 2022

LE STUDIUM Visiting Researcher 

From

Pázmány Péter Catholic University, Faculty of Information Technology and Bionics, HU

In residence at

Nanomedicines and Nanoprobes (NMNS), University of Tours - FR

Host scientist

Dr Franck Bonnier  

BIOGRAPHY

Franciska Erdő obtained her PhD from pharmacology at the Institute for Drug Research, Budapest and Semmelweis University, Faculty of Pharmacy, Budapest, Hungary. Later she worked for different biomedical research institutes (BIOREX Ltd, Veszprém, IVAX Drug Research Institute, Budapest) and joined the research group of Max Planck Institute for Neurological Research, Cologne, Germany and Charité University, Berlin, Germany. The main research interest of her was the investigation and experimental modelling of the pathophysiology of stroke, and development therapeutic strategies against stroke. Next she joined Sanofi-Aventis –Chinoin and SOLVO Biotechnology. Since November 2014 Franciska Erdő has been working for Pázmány Péter Chatholic University, Faculty of Information Technology and Bionics, Budapest. Her expertise is on the physiological barriers and drug delivery accross the barriers. Currently she is involved in skin analysis and RAMAN spectroscopy at University of Tours, France.

PROJECT

Knowledge transfer on Raman spectroscopy and skin-on-a-chip technology to study transdermal drug delivery

The transcutaneous route of drug administration provides huge benefits for the patients for confort (non-invasive) and efficacy (bypassing liver function, continuous and consistent drug release and absorption). It is important to develop proper drug formulations for various indications (pain, inflammation, central nervous system disorders, humoral therapies). During the last years the topical drug delivery techniques showed rapid development. Bioanalytical protocols play a key role in the investigation and optimization processes. Critical parameters of drug permeation such as bioavailabilty  and pharmacokinetics will be studied in this grant. In vitro testing is a pivotal step in the early stages of development of new formulas with high demands from the R&D and industry sectors for innovations.

Pázmány Péter Catholic University and University of Tours will work conjointly to address 2 key aspects:

1. In vitro Skin models: Commonly reconstructed skin from tissue culture or excised skin from plastic surgery are used for permeation studies. It is expected that in vitro models accurately mirror in vivo skin barrier function, hence deliver similar permeation to drugs to quickly identify and screen the most promising formulations and drugs. Presently, an innovative low-cost microfluidic technology will be developed: skin-on-a-chip. 

2. Analytical protocols: A multi-methodological analytical protocol coupling chromatography, Confocal Raman imaging and ultrasounds imaging will be developed to validate the skin-on-a-chip technology for skin permeation studies. Raman spectroscopy provides non-destructive and label free molecular characterisation of samples enabling to a) monitor drug diffusion in the skin to provide penetration profiles at micrometer scale and b) to construct biochemical maps of skin constituent distribution to study lipid and proteinorganisation and conformation. The permeation of drugs can be correlated to the skin barrier physiological state for a better understanding of molecular interactions between the skin and topical formula. 

LAST PUBLICATIONS

Ponmozhi J, Dhinakaran S, Varga-Medveczky Z, Fónagy K, Bors LA, Iván K, Erdő F.,Development of Skin-On-A-Chip Platforms for Different Utilizations: Factors to Be Considered. Micromachines (Basel). 2021 Mar 10;12(3):294. doi: 10.3390/mi12030294.

Bajza Á, Kocsis D, Berezvai O, Laki AJ, Lukács B, Imre T, Iván K, Szabó P, Erdő F. Verification of P-Glycoprotein Function at the Dermal Barrier in Diffusion Cells and Dynamic "Skin-On-A-Chip" Microfluidic Device. Pharmaceutics. 2020 Aug 25;12(9):804. doi: 10.3390/pharmaceutics12090804.